Lilly/BI get their DPP-IV combo

The Trajenta crowd has brought their combination product to the race with “Jentadueto”, the Trajenta/metformin offering.

This adds another option to the DPP-IV combination competition against Janumet and Kombiglyza.  We have been commenting in this space that the DPP-IV platform will likely see a myriad of combination approaches in the months to come. Merck’s Juvisync the most novel, combining Januvia with a statin. If alogliptin ever sees an audience with the FDA (see various posts on the ongoing agency delays for Takeda), we may see the first DPP-IV / TZD approach. is filled with multiple studies and multiple sponsors using various combinations with DPP-IVs.  Will any competitive efforts have any impact on the 800lb gorilla Januvia franchise?



Post a comment or leave a trackback: Trackback URL.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: